Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SCY-635

Small molecule · developed by Scynexis

Phase 2 Most advanced trial (none active)
SCYX Developer
1 Registered trials

What is SCY-635?

SCY-635 is an oral tablet studied in hepatitis C infection, given at 300 mg twice daily for 28 days in a trial.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Infectious disease
Developer
Scynexis, Inc. (SCYX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
WSU5343074

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01265511 Phase 2 Hepatitis C Infection Completed SCYX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis C Infection

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SCYX page.

Follow SCYX, the company behind SCY-635

See SCYX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SCYX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.